La vendita allo scoperto per Xilio Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Xilio Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Xilio Therapeutics (NASDAQ:XLO) Azioni, Report sulle vendite allo scoperto

Xilio Therapeutics

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Xilio Therapeutics Inc

Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), the heavyweight of Big Tech, has hit a grim milestone in technical analysis: <a href="https://www.benzinga.com/topic/death-cross">a Death Cross</a>. 
With its share price slipping below key moving averages, MSFT stock has moved into bearish territory, casting doubts on its near-term prospects. Is this just a blip for the software giant, or the prelude to deeper woes?
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25083136/Screenshot-2024-11-25-at-6.44.43-PM.png" alt="" class="wp-image-663339" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25083136/Screenshot-2024-11-25-at-6.44.43-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25083136/Screenshot-2024-11-25-at-6.44.43-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">MSFT Stock: Bearish Signals All Around</h2>
At $418.19, MSFT stock price trails its 20-day, 50-day and even the 200-day simple moving averages (SMAs). Technical indicators are sounding alarms:
<ul>
<li>The 20-day SMA at $418.73, the 50-day SMA at $421.65 and the 200-day SMA at $421.81 all point to a bearish signal.</li>
<li>The eight-day SMA at $417.37, continues to be driven by bullish sentiment over the short term, driven by buying pressure.</li>
<li>The Moving Average Convergence Divergence (MACD) stands at -1.11, another red flag.</li>
<li>The Relative Strength Index (RSI) at 49.09 suggests that Microsoft isn't oversold yet but is heading toward bearish momentum.</li>
</ul>
These technical markers paint a strongly bearish picture. Yet, buying pressure persists, indicating that investors still see potential for a turnaround—a glimmer of bullish hope amidst the gloom.
Read Also: <a href="https://www.benzinga.com/24/11/42160614/microsoft-ceo-satya-nadella-calls-for-culture-change-after-security-breaches-that-led-to-voluntary-pay-cut">Satya Nadella Promises &#8216;Culture Change&#8217; After Security Lapses Return To Haunt Microsoft 20 Years After Bill Gates Launched A Similar Initiative</a>
<h2 class="wp-block-heading">The ProPublica Bombshell</h2>
Compounding Microsoft's technical woes is a ProPublica investigation that has raised ethical and legal concerns over the company&#8217;s federal contracting practices. As detailed in the <a href="https://www.propublica.org/article/microsoft-white-house-offer-cybersecurity-biden-nadella">report</a>, Microsoft's "White House Offer"—a supposedly altruistic pledge to bolster government cybersecurity—was a calculated business maneuver. 
The plan involved providing free upgrades and consulting services to federal agencies, locking them into Microsoft's ecosystem. Once the "free" period ended, agencies had little choice but to continue with costly subscriptions and Azure services, effectively squeezing out competitors.
This strategy not only strengthened Microsoft's grip on federal business but also invited scrutiny for potentially violating federal procurement and antitrust laws. Legal experts argue that the deal sidesteps open competition, raising concerns about its long-term implications for government reliance on a single vendor.
<h2 class="wp-block-heading">A Double-Edged Sword</h2>
While the technical indicators signal bearishness, the buying pressure suggests a tug-of-war between short-term skepticism and long-term optimism. Microsoft's market dominance—bolstered by its lucrative cloud business and strategic maneuvers—remains a formidable moat. 
However, the ethical controversies surrounding its federal contracts could dent investor confidence and invite regulatory headwinds.
<h2 class="wp-block-heading">The Verdict</h2>
Microsoft's Death Cross is a wake-up call for investors. With the stock under technical pressure and the ProPublica revelations casting a shadow over its business practices, the path forward is murky. 
Bulls might see this as a chance to buy on weakness, banking on Microsoft's resilience. Bears, however, have a compelling case to remain cautious as the stock navigates this precarious juncture.
For now, Microsoft's crossroads is a reminder that even the mightiest of tech giants are not immune to scrutiny—or the market's harsh judgment.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/media/24/11/42136902/microsofts-brad-smith-urges-trump-government-to-tackle-growing-cyber-threats">Microsoft&#8217;s Brad Smith Urges Trump Government to Tackle Growing Cyber Threats</a></li>
</ul>
Image: Shutterstock

Long Ideas

Technicals

Signals

Tech

Trading Ideas

MSFT

Microsoft's Death Cross: Tech Giant Faces A Double Blow With FTC Pressure

SMTK

SmartKem Shares Halted On Circuit Breaker To The Downside, Stock Now Up 39.4%

<a href="https://www.theinformation.com/articles/apples-thin-iphone-has-no-physical-sims-that-could-dampen-china-sales" title="https://www.theinformation.com/articles/apples-thin-iphone-has-no-physical-sims-that-could-dampen-china-sales">https://www.theinformation.com/articles/apples-thin-iphone-has-no-physical-sims-that-could-dampen-china-sales</a>

News

AAPL

"Apple's Thin iPhone Has No Physical SIMs—That Could Dampen China Sales" - The Information

JMP Securities analyst Jordan Bender maintains MGM Resorts Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) with a Market Outperform and lowers the price target from $54 to $50.

Price Target

Analyst Ratings

JMP Securities Maintains Market Outperform on MGM Resorts Intl, Lowers Price Target to $50

Macro Economic Events

Econ #s

Economics

Dallas Fed Manufacturing Business Index For November -2.7 Vs -2.4 Est.; -3.0 Prior

William Blair analyst Jeff Schmitt initiates coverage on Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform rating.

Initiation

NDAQ

William Blair Initiates Coverage On Nasdaq with Outperform Rating

In the current session, the stock is trading at $116.06, after a 0.36% increase. Over the past month, Walt Disney Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) stock increased by 21.08%, and in the past year, by 25.83%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732548611_0.png" alt="Past Year Chart" />

<h3>Walt Disney P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Walt Disney has a lower P/E than the aggregate P/E of 52.76 of the Entertainment industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732548611_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Walt Disney

U.S. stocks settled higher on Friday, with the Dow Jones index closed at a fresh record level during the session. Major indices on the Wall Street recorded gains last week, with the Dow gaining around 2% and the S&amp;P 500 adding around 1.7%.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Trevor Walsh
<ul>
<li>Analyst Firm: JMP Securities</li>
<li>Ratings Accuracy: 89%</li>
<li>Latest Rating: Maintained a Market Outperform rating on Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) and raised the price target from $380 to $415 on Nov. 21. This analyst sees more than 8% increase in the stock.</li>
<li>Recent News: On Nov. 20, Palo Alto reported first-quarter revenue of $2.14 billion, beating the consensus estimate of $2.12 billion. The cybersecurity company reported quarterly earnings of $1.56 per share, beating analyst estimates of $1.48 per share, according to Benzinga Pro.</li>
</ul>
Analyst: Chris Kotowski
<ul>
<li>Analyst Firm: Oppenheimer</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Downgraded rating on JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) from Outperform to Perform on Nov. 20.</li>
<li>Recent News: On Nov. 7, J.P. Morgan Real Estate Income Trust, Inc. disclosed the acquisition of a two-site, three-building logistics and storage portfolio in Tampa and Pinellas Park, Florida, for $25.8 million, excluding closing costs.</li>
</ul>
Analyst: Andrew Kaplowitz
<ul>
<li>Analyst Firm: Citigroup</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Buy rating on Jacobs Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) and cut the price target from $166 to $161 on Nov. 20. This analyst sees around 19% upside in the stock.</li>
<li>Recent News: On Nov. 19, the company reported fourth-quarter revenue growth of 4.4% year-over-year to $2.96 billion, beating the consensus of $2.368 billion.</li>
</ul>
Analyst: Zachary Fadem
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained an Equal-Weight rating on Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) and increased the price target from $140 to $165 on Nov. 21. This analyst sees around 4% decline in the stock.</li>
<li>Recent News: On Nov. 20, Williams-Sonoma reported better-than-expected third-quarter financial results.</li>
</ul>
Analyst: Aaron Rakers
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained an Overweight rating on NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and raised the price target from $165 to $185 on Nov. 21. This analyst sees more than 30% upside in the stock.</li>
<li>Recent News: In a recent interview, Nvidia CEO Jensen Huang shared his thoughts on the company&#8217;s focus on supply as demand remains &#8220;incredible,&#8221; a development that was a big topic in the company&#8217;s recent financial results.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Pre-Market Outlook

NVDA

PANW

This Analyst With 85% Accuracy Rate Sees Over 30% Upside In Nvidia - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

JMP Securities analyst Jordan Bender maintains Golden Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEN#NASDAQ">GDEN</a>) with a Market Outperform and raises the price target from $35 to $36.

GDEN

JMP Securities Maintains Market Outperform on Golden Entertainment, Raises Price Target to $36

UBS analyst Joseph Spak maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Sell and raises the price target from $197 to $226.

TSLA

UBS Maintains Sell on Tesla, Raises Price Target to $226

WIIM

EVTL

Vertical Aerospace shares are trading higher after the company announced it secured an agreement where Mudrick Capital will commit up to $50 million in the next equity round.

Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) is giving traders a rollercoaster they can't resist. The server maker, famous for its AI systems powering Nvidia Corp's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips, saw its stock skyrocket 65% in a single week.
The stock opened the trading day of Monday, Nov. 18 at $20.03/share and closed Friday, Nov. 22 at $33.15/share. The stock was seen attempting to claw its way back from a six-month slump that wiped out nearly 60% of its value. 
But the road ahead is anything but smooth.
<h2 class="wp-block-heading">SMCI&#8217;s Nasdaq Drama: Staying In The Game</h2>
Super Micro recently faced a potential delisting scare after failing to meet Nasdaq's filing requirements. In response, the company hired a new independent auditor and vowed to file its earnings report soon. 
The stakes couldn't be higher; failure to follow through could wreak havoc on the stock, sending it into freefall once again. For now, though, traders appear to be betting on a redemption arc—just in time for the holidays.
Read Also: <a href="https://www.benzinga.com/tech/24/11/42008585/why-super-micros-survival-may-hinge-on-nvidia-earnings-nasdaq-deadline">Why Super Micro&#8217;s Future May Hinge On Nvidia Earnings, Nasdaq Deadline</a>
<h2 class="wp-block-heading">SMCI Stock&#8217;s Technical Tug-of-War</h2>
While last week's rally signals hope, SMCI's technical indicators paint a more nuanced picture. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25095056/Screenshot-2024-11-25-at-8.17.52-PM.png" alt="" class="wp-image-663488" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25095056/Screenshot-2024-11-25-at-8.17.52-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25095056/Screenshot-2024-11-25-at-8.17.52-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
SMCI stock, trading at $37.03, sits above its eight-day ($26.51) and 20-day ($27.06) simple moving averages (SMAs) — clear bullish signals. However, the longer-term outlook isn't as rosy. With the 50-day SMA at $38.00 and the 200-day SMA at a lofty $69.70, both point to bearish signals, reflecting the steep declines earlier this year.
Adding to the mixed signals, the moving average convergence/divergence (MACD) indicator stands at -2.63, further suggesting caution, while the relative strength index (RSI) hovers at 57.97, indicating neither overbought nor oversold conditions. 
It's a battleground for bulls and bears, and the options market <a href="https://www.tradingview.com/news/tradingview:82d432982094b:0-smci-super-micro-jumps-65-in-a-week-as-traders-ramp-up-bets-on-roaring-comeback/">implies</a> double-digit percentage swings could persist for weeks.
<h2 class="wp-block-heading">SMCI Stock From Boom To Bust — &amp; Back?</h2>
Super Micro shares once surged to over $122/share by March, riding the AI wave. But since peaking, the stock has shed 69% of its value as it trades around $38/share &#8211; leaving investors wondering if the magic is gone for good. 
Even after the recent rally, the stock has only managed a modest 33.70% gain year-to-date.
<h3 class="wp-block-heading">The Comeback Question</h3>
With Nasdaq compliance hanging in the balance and volatility dominating its trading patterns, Super Micro has a lot to prove. Can the server manufacturer capitalize on its AI-driven partnerships and rebuild investor trust, or will it face another wipe out?
Traders are watching closely, and the clock is ticking.
For now, Super Micro is a high-stakes bet. The potential rewards are tantalizing, but the risks? They're towering, too.
Read Also: 
<ul>
<li><a href="https://benzinga.com/news/earnings/24/11/42160175/us-stocks-likely-to-open-on-a-positive-note-as-trumps-treasury-secretary-pick-uplifts-investor-sentiment-expert-says-bull-market-is-alive-and-well">US Stocks Likely To Open On A Positive Note As Trump&#8217;s Treasury Secretary Pick Uplifts Investor Sentiment: Expert Says &#8216;Bull Market Is Alive And Well&#8217;</a></li>
</ul>
Image: Shutterstock

Movers

SMCI

SMCI Surges 65% In A Week, But Is Volatility The New Normal?

Macy's <a href="https://www.benzinga.com/24/11/42162655/macy-falls-as-preliminary-q3-highlights-mixed-performance-and-154-million-expense-concealment">delayed its Q3 earnings release</a>, revealing an internal investigation into an employee who allegedly hid hundreds of millions of dollars in expenses.
Shares of Macy&#8217;s, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) are trading lower on Monday, and there is a good chance that the downtrend will continue.
This is why it is our Stock of the Day.
A person who was responsible for small package delivery expense accounting made intentional &#8220;erroneous accounting accrual entries.&#8221; As much as $154 million may have been hidden. The activity occurred between Q4 2021 and the current third quarter.
Macy's said there was &#8220;no indication that the accounting error had any impact on the cash management activities or vendor payments.&#8221; It also said the employee is no longer with the company.
Read Also: <a href="https://www.benzinga.com/news/24/11/42093639/why-macys-stock-is-falling">Why Macy&#8217;s Stock Is Falling</a>
The stock was looking technically vulnerable prior to the news coming out. As you can see on the chart, it had run into resistance again around the $16.40 level. Stocks tend to sell off after they hit resistance. This is what happened with Macy's in mid-October and early November.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25101907/m-chart-1024x557.webp" alt="" class="wp-image-663574" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25101907/m-chart-1024x557.webp 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25101907/m-chart-300x163.webp 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25101907/m-chart-768x418.webp 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25101907/m-chart.webp 1501w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
When a stock trends higher, there aren't enough sellers to fill all the buy orders. As a result, buyers are forced to bid successively higher prices to attract sellers into the market, forcing the stock into an uptrend.
When resistance is reached, the uptrend ends. There are more than enough sellers to fill all of the buy orders. Buyers can acquire all of the shares they wish to without pushing the price any higher.
Sometimes, some investors and traders who create resistance with their sell orders become concerned. They know the buyers will go to whoever will sell at the lowest price.
They fear that other sellers may lower their asking prices, prompting them to do the same. This behavior often triggers a chain reaction, with more sellers reducing their prices in response.
It results in a snowball effect that can push the price lower.
This is what happened the last two times Macy's reached the $16.40 level, and it may be about to happen again.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/42154628/larry-page-google-co-founder-said-hed-leave-his-fortune-to-elon-musk-over-charity-because-of-his-plans-to-go-to-mars-to-back-up-humanity">Larry Page, Google Co-Founder, Said He&#8217;d Leave His Fortune To Elon Musk Over Charity Because Of His Plans &#8216;To Go To Mars To Back Up Humanity&#8217;</a></li>
</ul>
Photo: Shutterstock

Stock Of The Day: Macy's Hits Resistance Following Accounting Scandal

BCOV

Brightcove shares are trading higher after the company announced it entered into a definitive agreement to be acquired by Bending Spoons.

SmartKem shares are trading higher after the company announced it partnered with AUO to jointly develop a rollable, transparent microLED display.

JMP Securities analyst Jordan Bender maintains Caesars Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) with a Market Outperform and lowers the price target from $59 to $57.

JMP Securities Maintains Market Outperform on Caesars Entertainment, Lowers Price Target to $57

QMCO

Quantum Corp Shares Resumed Trade

U.S. stocks were higher, with the Dow Jones index gaining more than 400 points on Monday.
Shares of BridgeBio Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) rose sharply during Monday's session after the company announced that the FDA approved Attruby to <a href="https://www.benzinga.com/24/11/42163927/fda-approves-bridgebio-pharmas-drug-for-rare-heart-disease-poised-to-challenge-pfizer-in-lucrative-yet-competitive-market">treat adults with ATTR-CM.</a>
On Friday, the FDA approved BridgeBio Pharma's Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. Also, HC Wainwright maintained a Buy rating on the stock and raised its price target from $43 to $49.
BridgeBio Pharma shares jumped 22.3% to $28.64 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) shares jumped 69% to $2.9289 after the company completed a $100 million at-the-market equity offering, with plans to use the proceeds for working capital, capital expenditures, and advancements in superconducting quantum computing technology.</li>
<li>Scholar Rock Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) gained 27.2% to $38.03. Scholar Rock Holding recently reported worse-than-expected third-quarter EPS results.</li>
<li>D-Wave Quantum Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NASDAQ">QBTS</a>) surged 26.3% to $3.6800 after AWS announced Quantum Embark program.</li>
<li>Mercurity Fintech Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) gained 23.3% to $6.15.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) rose 19% to $7.26 after AWS announced Quantum Embark program.</li>
<li>Eastman Kodak Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KODK#NYSE">KODK</a>) surged 17.4% to $6.18.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) rose 16.6% to $38.36.</li>
<li>Eve Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVEX#NYSE">EVEX</a>) gained 16.6% to $3.9062.</li>
<li>Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) shares climbed 15.5% to $35.49 after the company reported better-than-expected third-quarter EPS and sales and raised its 2024 guidance.</li>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) surged 14.6% to $6.92.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) rose 13.5% to $28.77.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) gained 11.3% to $9.52.</li>
<li>Clarivate Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLVT#NYSE">CLVT</a>) rose 8.7% to $5.70.</li>
<li>Flagstar Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLG#NYSE">FLG</a>) gained 7.1% to $12.52.</li>
<li>Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) climbed 6.8% to $92.82. Five Below will release its financial results for the third quarter of fiscal 2024 after the closing bell on Wednesday, Dec. 4.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) climbed 6.3% to $43.74.</li>
<li>Jones Lang LaSalle Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>) gained 6.1% to $279.28. Wolfe Research analyst Andrew Rosivach upgraded Jones Lang LaSalle from Peer Perform to Outperform and announced a $353 price target.</li>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) rose 6% to $114.49 after Wedbush upgraded the stock from Neutral to Outperform and announced a $135 price target.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

ACHR

BBIO

BBWI

CLVT

ESTC

EVEX

FIVE

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IOVA

KODK

MRNA

QBTS

QUBT

RGTI

SRRK

BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday

Citigroup analyst Keith Horowitz maintains PNC Finl Servs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) with a Buy and raises the price target from $200 to $235.

Citigroup Maintains Buy on PNC Finl Servs Gr, Raises Price Target to $235

Israel and Lebanon have agreed on the framework for a cease-fire deal to end over a year of violent conflict between Israel and Hezbollah, a senior U.S. official told Axios on Monday.
While the agreement awaits formal approval from Israel's Security Cabinet on Tuesday, global financial markets are already reacting, with gold and oil prices tumbling as geopolitical risks recede and risky assets soar<a href="https://www.benzinga.com/topic/israel"> amid improving investor optimism. </a>
Both the Dow Jones Index and the S&amp;P 500 indices hit fresh record highs minutes following Monday&#8217;s market open in New York. 
<h3 class="wp-block-heading">Israel-Lebanon Deal: What It Includes</h3>
The cease-fire, if approved, would mark the end of a bloody chapter that has claimed the lives of over 3,500 Lebanese and 140 Israelis while displacing hundreds of thousands of people on both sides of the border. 
Under the proposed agreement, Israel would initiate a 60-day withdrawal of its military from southern Lebanon, the <a href="https://www.axios.com/2024/11/25/israel-lebanon-near-hezbollah-ceasefire-deal">Axios report said</a>. 
Simultaneously, the Lebanese army would deploy along border areas, and Hezbollah would relocate its heavy weaponry north of the Litani River.
To ensure compliance, a U.S.-led oversight committee would monitor the agreement, while the U.S. has pledged to support Israeli military action against imminent threats if Lebanese forces fail to act.
A senior U.S. official told Axios: "We think we have a deal. We are on the goal line, but we haven't passed it yet."
<h3 class="wp-block-heading">Oil, Gold Take A Blow</h3>
The news sent shockwaves through the commodities market. 
With the threat of broader regional conflict subsiding, West Texas Intermediate (WTI) crude oil – as tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) – fell 1.5% on Monday to $70 per barrel, almost fully paring back Friday&#8217;s gains. 
Gold, tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) plunged over 3% to $2,640 an ounce as investors scaled back safe-haven bets. Silver followed suit, dropping 3% to $30.40 an ounce. 
The U.S. dollar also softened, losing 0.7% against a basket of major currencies, reflecting the shift in risk sentiment.
<h3 class="wp-block-heading">Stock Market Soars To New Heights</h3>
The cease-fire optimism spilled into equities. The S&amp;P 500 index – tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) –reached an all-time high of 6,020 points, gaining 0.8% on the day, while the Dow Jones Industrial Average – mimicked by the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) – climbed 1% to a record-breaking 44,738.
Notably, all major S&amp;P sectors except energy posted gains, with the broader index aiming for its sixth straight session of gains.
Israeli stocks – tracked by the VanEck Israel ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ISRA#NYSE">ISRA</a>) – soared 1.9%, also eyeing a six-day winning streak.
S&amp;P 500&#8217;s top gainers during morning trading in New York included: 
<ul>
<li>Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>)</li>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>)</li>
<li>Clarivate Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLVT#NYSE">CLVT</a>)</li>
<li>Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>)</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42165391/vanguards-sp-500-etf-hits-100-billion-inflows-in-2024-is-spys-crown-at-risk">Vanguard&#8217;s S&amp;P 500 ETF Hits $100 Billion Inflows In 2024: Is SPY&#8217;s Crown At Risk?</a></li>
</ul>
Photo via Shutterstock.

Equities

Broad U.S. Equity ETFs

Emerging Markets

Specialty ETFs

Emerging Market ETFs

Commodities

Politics

Global

ETFs

ALAB

SPDR Dow Jones Industrial Average ETF Trust

ISRA

WOLF

Israel, Lebanon Reach Reported Cease-Fire Deal: Gold, Oil Tumble; S&P 500, Dow Jointly Hit Record Highs

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Xilio Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/xlo-stock-quote/">XLO</a>) just reported results for the first quarter of 2024.<ul><li>Xilio Therapeutics reported earnings per share of -59 cents. This was below the analyst estimate for EPS of -11 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/xlo-stock-earnings-xilio-therapeutics-for-q1-of-2024/">XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024

Xilio Therapeutics (XLO) has provided an update. Xilio Therapeutics, Inc. has expanded its Board of Directors to nine members, welcoming James Shan...

Xilio Therapeutics Enhances Board with Two New Directors

Xilio Therapeutics GAAP EPS of -$0.24, revenue of $2.4M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Xilio Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/xlo-stock-quote/">XLO</a>) just reported results for the second quarter of 2024.<ul><li>Xilio Therapeutics reported earnings per share of -24 cents. This was below the analyst estimate for EPS of -23 cents.</li><li>The company reported revenue of $2.36 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/xlo-stock-earnings-xilio-therapeutics-for-q2-of-2024/">XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q2 2024

TD Cowen analyst Marc Frahm maintained a Buy rating on Xilio Therapeutics (XLO – Research Report) yesterday. The company's shares closed yesterday ...

TD Cowen Remains a Buy on Xilio Therapeutics (XLO)

Xilio Therapeutics ( ($XLO) ) has shared an announcement. Xilio Therapeutics announced significant progress in its pipeline and financial updates f...

Xilio Therapeutics Advances Cancer Drug and Financial Outlook

TD Cowen analyst Marc Frahm maintained a Buy rating on Xilio Therapeutics (XLO – Research Report) today. The company's shares closed today at $1.04...

TD Cowen Keeps Their Buy Rating on Xilio Therapeutics (XLO)

Xilio Therapeutics Inc ( ($XLO) ) has released its Q3 earnings. Here is a breakdown of the information Xilio Therapeutics Inc presented to its inve...

Xilio Therapeutics Reports Q3 2024 Progress and Financials

Xilio Therapeutics reports Q3 results

Morgan Stanley analyst Michael Ulz has maintained their bullish stance on XLO stock, giving a Buy rating yesterday. Michael Ulz has given his Buy r...

Promising Pipeline and Financial Stability Drive Buy Rating for Xilio Therapeutics

Earnings

Press Releases

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

Management

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Health Care

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

Comments

Xilio Therapeutics

Vendite allo scoperto

Xilio Therapeutics (NASDAQ:XLO) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO